View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 26, 2011

PSA test could predict low-risk prostate cancer, says study

A study by Mayo clinic has found that the prostate-specific antigen (PSA) test could be a vital tool in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer.

A study by Mayo clinic has found that the prostate-specific antigen (PSA) test could be a vital tool in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer.

The study reported that men in their 40s and 50s with a baseline PSA at or above the median PSA are more likely to undergo a biopsy and be diagnosed with low-risk prostate cancer.

The PSA test measures the amount of PSA, a protein produced by cells of the prostate gland, in the patient’s blood. It allows physicians to determine a patient’s potential risk of developing prostate cancer.

High PSA levels may occur due to benign prostate enlargement or inflammation of the urinary tract.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management